Garuda Therapeutics

Executive Summary

Garuda Therapeutics is pioneering an off-the-shelf hematopoietic stem cell (HSC) therapy platform designed to create universal donor stem cells that are immune-evasive, eliminating the need for patient-matched donors. This approach has the potential to cure genetic blood disorders, treat cancers, and enable more accessible cell therapies. The company has raised $112 million in funding and is currently in the preclinical stage, with a focus on advancing its lead program toward clinical development. Garuda's technology addresses a critical bottleneck in stem cell transplantation by providing a standardized, readily available product that could replace the complex donor matching process, significantly expanding patient access and reducing treatment delays. The platform's versatility also positions it as a foundational technology for future cell therapy combinations, potentially transforming the treatment landscape for hematologic malignancies and inherited blood diseases.

Upcoming Catalysts (preview)

• TBDIND Filing for Lead Program50% success
• H2 2026Next Financing Round (Series B or C)75% success
• Q3 2026Preclinical Proof-of-Concept Data Publication80% success